What should I do if I become drug-resistant after taking Vorinostat?
Histone deacetylase inhibitors (HDACi) showed promising activity against hematological malignancies in clinical trials and led to the approval of vorinostat for the treatment of cutaneous T-cell lymphoma. However, as with many cancer therapies, de novo resistance is common, and acquired resistance is inevitably accompanied by sensitivity. Vorinostat-resistant cells are cross-resistant to other HDACi, but not all. Resistant cells have increased sensitivity to the proteasome inhibitor bortezomib and the autophagy inhibitor chloroquine.
Doctors may choose more effective targeted drugs or combination drug regimens by analyzing the genetic mutations of tumor cells and the activity of related signaling pathways. After resistance is determined, doctors may recommend trying other treatment options, such as switching to a different anticancer drug or using combination therapy. Immunotherapy can also be used to combat drug resistance. Immunotherapy can overcome drug resistance by activating the patient's own immune system to attack cancer cells. In addition, participating in clinical trials is an option, especially for new treatments targeting drug resistance. Clinical trials can provide the latest treatment options and help advance scientific advances in cancer treatment. Since everyone's constitution is different, their resistance to drugs is also different. If drug resistance occurs after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.
The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)